Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 725-735

  Giuliani, Rosa ^a   Durbecq, Virginie ^a   Di Leo, Angelo ^a   Paesmans, Marianne ^a   Larsimont, Denis ^a   Leroy, Jean Yves ^a   Borms, Marleen ^b   Vindevoghel, Anita ^c   Jerusalem, Guy ^d   D'Hondt, Veronique ^e   Dirix, Luc ^f   Canon, Jean Luc ^g   Richard, Vincent ^h   Cocquyt, Veronique ⁱ   Majois, Françoise ^j   Reginster, Michel ^f   Demol, Jan ^k   Kains, Jean Pierre ^l   Delree, Paul ^m   Keppens, Carine ⁿ   Sotiriou, Christos ^a   Piccart, Martine J ^a   Cardoso, Fatima ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b AZ GROENINGE   (Belgium)

^c Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^d CHU SART TILMAN   (Belgium)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f Medical Oncology   (Belgium)

^g Clinique Notre Dame   (Belgium)

^h Department of Nephrology   (Belgium)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j Hospital de Jolimont   (Belgium)

^k Medical Oncology   (Belgium)

^l IRIS   (Belgium)

^m Pathology   (Belgium)

ⁿ F Hoffman La Roche Ltd   (Belgium)

more..

Author keywords

Metastatic breast cancer; Phosphorylated HER 2; Predictive factors; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 34047123086     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.11.019     Document Type: Article

References (50)

1. Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 (1997) 1647-1655
2. Olayioye M.A., Neve M.R., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
3. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 (2001) S3-S8
4. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
5. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235 (1987) 177-182
6. Carter P., Presta L., Gorman C., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 (1992) 4285-4289
7. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
8. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of T as single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
9. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
10. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. The Oncologist 9 Suppl. 3 (2004) 20-26
11. Baselga J., and Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 Suppl. 1 (2001) 35-41
12. Baselga J., Albanell J., Molina M.A., and Arribas J. Mechanism of action of T and scientific update. Semin Oncol 28 Suppl. 16 (2001) 4-11
13. Molina M.A., Codony-Servat J., Albanell J., et al. T (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (2001) 4744-4749
14. Pegram M.D., and Reese D.M. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and Vascular Endothelial Growth Factor. Semin Oncol 29 Suppl. 11 (2002) 29-37
15. Cardoso F., Piccart M.J., Durbecq V., and Di Leo A. Resistance to T: a necessary evil or a temporary challenge?. Clin Breast Cancer 3 (2000) 247-255
16. kip1 via multiple signalling pathways. Cell Cycle 4 1 (2005) [Epub ahead of print]
17. Yakes M.F., Chinratanalab W., Ritter C., et al. Herceptin-induced inhibition of Phosphatidylinositol-3 Kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62 (2002) 4132-4141
18. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, T, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 (2002) 707-717
19. Neve R.M., Lane H.A., and Hynes N.E. The role of overexpressed HER2 in transformation. Ann Oncol 12 Suppl. 1 (2001) S9-S13
20. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene 18 (1999) 2241-2251
21. Yu D., and Hung M.-C. Role of erbB2 in breast cancer chemosensitivity. BioEssays 22 (2000) 673-680
22. ®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58 (1998) 2825-2831
23. Lee S., Yang W., Lan K.-H., et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62 (2002) 5703-5710
24. cdc2 activation and is involved in resistance to taxol induced apoptosis. Mol Cell 23 3B (2002) 2275-2279
25. Yu D., and Hung M.-C. Therapeutic resistance of erbB-2-overexpressing cancers and strategies to overcome this resistance. In: Erlich M. (Ed). DNA alterations in cancer (2000), Eaton Publishing, Natick (MA) 457-470
26. Gancberg D., Di Leo A., Cardoso F., et al. Ann Oncol 13 (2002) 1036-1043
27. Naidu R., Yadav M., Nair S., and Kutty M.K. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78 (1998) 1385-1390
28. Thor A.D., Liu S., Edgerton S., et al. Activation (tyrosine phosphorylation) of ErbB2 (HER2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 15 (2000) 3230-3239
29. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124
30. Pohl G., Rudas M., Dietze O., et al. High p27kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus Goserelin. J Clin Oncol 21 (2003) 3594-3600
31. Tan P., Cady B., Wanner M., et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 57 (1997) 1259-1263
32. Catzavelos C., Bhattacharya N., Ung Y.C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3 (1997) 227-230
33. Wu J., Shen A.A., Lu J.S., et al. Prognostic role of p27Kip1 and apoptosis in human breast cancer. Br J Cancer 79 (1999) 1572-1578
34. Esteva F.J., Sahin A.A., Smith T.L., et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100 (2004) 499-506
35. Leake R., Barnes D., Pinder S., et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. J Clin Pathol 53 (2000) 634-635
36. Bell R., Verma S., Untch M., Cameron D., and Smith I. Maximizing clinical benefit with T. Semin Oncol 31 Suppl. 10 (2004) 35-44
37. Holbro T., Beerli R., Maurer F., et al. Proc Natl Acad Sci USA 100 (2003) 8933-8938
38. Hudelist G., Köstler W.J., Attems J., et al. Her-2/neu triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of T-based treatment. Br J Cancer 89 (2003) 983-991
39. Leyland-Jones B., Marty M., Baselga J., et al. HER2 extracellular domain (ECD) levels do not predict clinical response or time course of progression, in patients (pts) with metastatic breast cancer (MBC) or non-small cell lung cancer (NSCLC). Ann Oncol 15 (2004) [abstract 510]
40. Ali S.M., Esteva F.J., Fornier M., et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. Proc ASCO 24 (2006) [abstract 500]
41. Esteva F.J., Cheli C.D., Fritsche H., et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7 (2005) R436-R443
42. Kostler W.J., Schwab B., Singer C.F., et al. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10 (2004) 618-624
43. Saez R., Molina M.A., Ramsey E., et al. p95HER-2 predicts worse outcome in patients with HER-2 positive breast cancer. Clin Cancer Res 12 (2006) 424-431
44. mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene 16 (1998) 2087-2094
45. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell-lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
46. Paez J.G., Jänne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefinitib therapy. Science 304 (2004) 497-1500
47. Sthephens P., Hunter C., Bignell G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431 (2004) 525-526
48. Nagata Y., Lan K.-H., Zhou X., et al. PTEN activation contributes to tumor inhibition by T, and loss of PTEN predicts T resistance in patients. Cancer Cell 6 (2004) 117-127
49. Chan-Hui P.-Y., Stephens K., Warnock R.A., et al. Applications of eTag assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 111 (2004) 162-174
50. Dowsett M., Gutierrez C., Mohsin S., et al. Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2, and P38-MAP-kinase. Proc ASCO 22 (2003) [abstract 7]